, Tracking Stock Market Picks
Enter Symbol:
Rating: RXII

galena biopharma (NASDAQ: GALE) downgraded to Hold by Cantor Fitzgerald

Tuesday,  Dec 8, 2015  10:25 AM ET by Dave Ficere

Cantor Fitzgerald downgraded galena biopharma (NASDAQ: GALE) to Hold. Previously
Cantor Fitzgerald rated Buy with price target $4 galena biopharma (NASDAQ: GALE) on 06/04/2012, when the stock price was $1.50.

RXi Pharmaceuticals Corporation (RXi) is a discovery-stage biopharmaceutical company pursuing therapeutics based on ribonucleic acid interference (RNAi) for the treatment of human diseases. The Company is focused on internal research and development programs on certain inflammatory and metabolic diseases, and to pursue other therapeutic areas with potential partners. RXi commenced operations after CytRx Corporation contributed to the Company its portfolio of RNAi therapeutic assets, which consisted primarily of RNAi licenses and related intellectual property, and a nominal amount of equipment. As of December 31, 2008, the Company had not generated any revenues.

Cantor U.S. Equity Research provides timely and insightful opinions on select stocks. We look at key drivers of the stock price, including company and industry fundamentals, capital markets influences and overall economic trends to provide critical and in-depth analysis. Our focus is on small and mid-cap companies in the following sectors: * Marine Transportation * Life Sciences * Clean Technology & Energy Efficiency * Real Estate * Communications Technology * Internet * Enterprise Software

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy